Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules.

Mouri A, Nagai T, Ibi D, Yamada K.

Neurobiol Dis. 2013 May;53:61-74. doi: 10.1016/j.nbd.2012.10.025. Epub 2012 Nov 6. Review.

PMID:
23142533
2.

The potential role of lamotrigine in schizophrenia.

Large CH, Webster EL, Goff DC.

Psychopharmacology (Berl). 2005 Sep;181(3):415-36. Epub 2005 Oct 12. Review.

PMID:
16001126
3.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA.

Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Epub 2012 May 15. Review.

PMID:
22584864
4.

[Targeting metabotropic glutamate receptors to develop novel antipsychotics].

Chaki S, Yoshida S, Okuyama S.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Nov;30(5-6):207-13. Review. Japanese.

PMID:
21226317
5.

Animal models for predicting the efficacy and side effects of antipsychotic drugs.

Gobira PH, Ropke J, Aguiar DC, Crippa JA, Moreira FA.

Rev Bras Psiquiatr. 2013;35 Suppl 2:S132-9. doi: 10.1590/1516-4446-2013-1164. Review.

6.

Behavioral animal models of antipsychotic drug actions.

Peleg-Raibstein D, Feldon J, Meyer U.

Handb Exp Pharmacol. 2012;(212):361-406. doi: 10.1007/978-3-642-25761-2_14. Review.

PMID:
23129339
7.

Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.

de Bartolomeis A, Sarappa C, Magara S, Iasevoli F.

Eur J Pharmacol. 2012 May 5;682(1-3):1-11. doi: 10.1016/j.ejphar.2012.02.033. Epub 2012 Feb 24. Review.

PMID:
22387855
8.

Novel pharmacological approaches to the treatment of schizophrenia.

Fink-Jensen A.

Dan Med Bull. 2000 Jun;47(3):151-67. Review.

PMID:
10913983
9.

Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?

Ellenbroek BA.

Neuropharmacology. 2012 Mar;62(3):1371-80. doi: 10.1016/j.neuropharm.2011.03.013. Epub 2011 Mar 21. Review.

PMID:
21420988
11.

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.

Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK.

Pharmacol Ther. 2010 Dec;128(3):419-32. doi: 10.1016/j.pharmthera.2010.07.004. Epub 2010 Aug 10. Review.

PMID:
20705091
12.

Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models.

Watanabe Y, Someya T, Nawa H.

Psychiatry Clin Neurosci. 2010 Jun;64(3):217-30. doi: 10.1111/j.1440-1819.2010.02094.x. Review.

13.

Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Deng C, Pan B, Engel M, Huang XF.

Psychopharmacology (Berl). 2013 Mar;226(2):201-15. doi: 10.1007/s00213-013-3003-2. Epub 2013 Feb 7. Review.

PMID:
23389757
14.

The changing roles and targets for animal models of schizophrenia.

Kilts CD.

Biol Psychiatry. 2001 Dec 1;50(11):845-55. Review. Erratum in: Biol Psychiatry 2002 Feb 15;51(4):346.

PMID:
11743940
15.

Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.

Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG Jr, Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA.

Neuropharmacology. 2013 Jan;64:254-63. doi: 10.1016/j.neuropharm.2012.07.017. Epub 2012 Jul 21.

PMID:
22824189
16.

Bringing order to the glutamate chaos in schizophrenia.

Moghaddam B.

Neuron. 2003 Dec 4;40(5):881-4. Review.

17.
18.

Schizophrenia: from dopamine to glutamate and back.

Carlsson ML, Carlsson A, Nilsson M.

Curr Med Chem. 2004 Feb;11(3):267-77. Review.

PMID:
14965231
19.

Behavioral phenotypes for negative symptoms in animal models of schizophrenia.

Miyamoto Y, Nitta A.

J Pharmacol Sci. 2014;126(4):310-20. doi: 10.1254/jphs.14R02CR. Epub 2014 Nov 18. Review.

20.

Conditioned avoidance response in the development of new antipsychotics.

Wadenberg ML.

Curr Pharm Des. 2010 Jan;16(3):358-70. Review.

PMID:
20109144

Supplemental Content

Support Center